Deficiency of α-1-antitrypsin influences systemic iron homeostasis

Andrew J Ghio
Joleen M Soukup
Judy H Richards
Bernard M Fischer
Judith A Voynow
Donald E Schmechel

US Environmental Protection Agency, Chapel Hill, NC, USA; Division of Pediatric Pulmonary Medicine, Department of Pediatrics, Joseph and Kathleen Bryan Alzheimer Disease Research Center, Department of Medicine (Neurology), Duke University Medical Center, Durham, NC, USA

Abstract: There is evidence that proteases and antiproteases participate in the iron homeostasis of cells and living systems. We tested the postulate that α-1 antitrypsin (A1AT) polymorphism and the consequent deficiency of this antiprotease in humans are associated with a systemic disruption in iron homeostasis. Archived plasma samples from Alpha-1 Foundation (30 MM, 30 MZ, and 30 ZZ individuals) were analyzed for A1AT, ferritin, transferrin, and C-reactive protein (CRP). Plasma samples were also assayed for metals using inductively coupled plasma atomic emission spectroscopy (ICP AES). Plasma levels of A1AT in MZ and ZZ individuals were approximately 60% and 20% of those for MM individuals respectively. Plasma ferritin concentrations in those with the ZZ genotype were greater relative to those individuals with either MM or MZ genotype. Plasma transferrin for MM, MZ, and ZZ genotypes showed no significant differences. Linear regression analysis revealed a significant (negative) relationship between plasma concentrations of A1AT and ferritin while that between A1AT and transferrin levels was not significant. Plasma CRP concentrations were not significantly different between MM, MZ, and ZZ individuals. ICP AES measurement of metals confirmed elevated plasma concentrations of nonheme iron among ZZ individuals. Nonheme iron concentrations correlated (negatively) with levels of A1AT. A1AT deficiency is associated with evidence of a disruption in iron homeostasis with plasma ferritin and nonheme iron concentrations being elevated among those with the ZZ genotype.

Keywords: α-1-antitrypsin deficiency, serpins, proteinase inhibitor proteins, ferritin, transferrin

Introduction

Alpha-1 antitrypsin (A1AT; also known as α-1 proteinase inhibitor) is a serum glycoprotein which predominantly (80%) originates from hepatocytes. A1AT inhibits a wide variety of proteases (eg, neutrophil elastase and proteinase-3) to contribute to a proteinase/antiproteinase balance. It is postulated that this acute phase protein participates in limiting host tissue injury by proteases at sites of inflammation; a proposed critical function is the prevention of lung injury associated with disruption of connective tissue by neutrophil elastase enzyme.

A1AT deficiency is an autosomal recessive genetic disorder caused by its defective production leading to both decreased activity in body tissues and deposition of excessive abnormal protein in the liver. While M is the normal allele for A1AT, there are over 80 variant mutations of the gene. The Z allele results in a glutamate to lysine mutation at position 342 while the S allele produces a glutamate to valine mutation at position 324. In individuals with SS, MZ and SZ genotypes, blood levels...
of A1AT are reduced to between 40% and 60% of normal levels (ie, those observed among MM individuals). Among those who do not smoke, this A1AT concentration is almost always sufficient to protect the lungs from the effects of elastase. However, among individuals with the ZZ genotype, A1AT levels are usually less than 15% of normal and these deficient patients can develop lung disease at a young age. In addition, those with the ZZ genotype can develop liver disease; this is associated with impaired A1AT secretion and its consequent accumulation in this specific tissue. Therefore, A1AT deficient patients can present with lung disease (eg, panacinar emphysema [chronic obstructive pulmonary disease], pneumothorax, asthma, and bronchiectasis) and liver disease (eg, hepatitis, cirrhosis, and hepatocellular carcinoma).4 People of northern and western European ancestry are at the greatest risk for A1AT deficiency and its associated diseases;5 4% carry the PiZ allele and between 1 in 1,500 and 1 in 2,500–3,000 are ZZ.

In addition to siderophores and ferrireductases, microbials employ proteases to mobilize host sources of iron to support their growth and replication.6 These proteases cleave iron-transport and -storage proteins allowing utilization of the metal by the microbe.7,8 Corroborating a potential interaction between metal homeostasis and proteases, elevated iron concentrations impact expression of proteases and their activities.9–12 Animal and human investigation similarly suggests a participation of proteases in iron homeostasis,13–15 The intratracheal instillation of a single dose of neutrophil elastase in an animal model increased lung iron concentrations. Iron homeostasis is disrupted among cystic fibrosis patients in whom airway elastase content and activity is excessive; cystic fibrosis patients have elevated iron and ferritin concentrations in both the sputum and bronchoalveolar lavage.

A participation of proteases also suggests a potential involvement of anti-proteases in iron homeostasis. A1AT is the antiprotease in greatest concentration in humans. A participation of A1AT in the iron homeostasis of humans has been previously suggested with observations of deficient patients developing cirrhosis characterized by significant iron accumulation.16 An involvement of neutrophil elastase and A1AT in disrupting iron homeostasis of the lung was supported by investigation which demonstrated a proteolytic cleavage of both iron-transport and -storage proteins with subsequent increase in nonheme tissue iron concentrations.17 Finally, patients treated with antiproteases, and thus altering protease activity, can show evidence of disruptions in iron homeostasis.18 We further explored the relationship between A1AT and iron homeostasis in humans by testing the postulate that its deficiency is associated with a systemic disruption in iron homeostasis.

Methods
Samples from MM, MZ, and ZZ individuals
Archived plasma samples were kindly provided by the Alpha-1 Foundation (Miami, FL). These included 90 nonfasting plasma specimens from 30 MM, 30 MZ, and 30 ZZ individuals who had been screened as family members of a patient with A1AT deficiency. The health status of the donor was not known. Institutional Review Board exemption was granted from the University of North Carolina for analyses of these blood samples.

Plasma assays
Samples were analyzed for A1AT, ferritin, iron, transferrin, and C-reactive protein (CRP). A1AT and CRP concentrations were measured using immunoturbidimetric assay kits (Diasorin Inc, Stillwater, MN). Ferritin was quantified by also using an immunoturbidimetric assay (Kamiya Biomedical Company, Seattle, WA). Transferrin concentrations were analyzed using an immunoprecipitation analysis (INCASTAR Corporation, Stillwater, MN). Assays were modified for use on the Konelab Arena 30 (ThermoLab Systems, Espoo, Finland).

Measurements of metals in plasma
Plasma samples were hydrolyzed at 70°C in 3 N HCl/10% trichloroacetic acid for 24 hours. After centrifugation, metals in the supernatant were measured using inductively coupled plasma optical emission spectroscopy (ICPOES; Model Optima 4300D; Perkin Elmer, Norwalk, CT).

Statistics
Data are expressed as mean values ± standard error unless otherwise specified. Differences between groups were compared using one-way analysis of variance. The post-hoc test employed was Duncan’s Multiple Range test. General linear regression modeling was used in delineating a relationship between two continuous variables. Significance was assumed at P < 0.05.

Results
Demographics of healthy individuals providing archived plasma samples are listed (Table 1). There were differences in the gender distributions between the MM, MZ, and ZZ cohorts and subsequently results were provided for males and females. Disparities in age and ethnicity between the cohorts were not significant.
Among the samples collected by the Alpha-1 Foundation, plasma levels of A1AT for MZ and ZZ individuals were approximated as 60% and 20% of those for MM individuals respectively (Figure 1A). This concentration of A1AT approximates those serum values reported in other study populations in which ZZ individuals demonstrate levels 15% of MM subjects. There were significant differences in plasma ferritin concentrations between MM, MZ, and ZZ cohorts (Figure 1B). Those with the ZZ genotype showed greater ferritin values relative to both MM and MZ genotypes while there were no differences between MM and MZ (Figure 1B; F = 5.54; P = 0.02). When separate analyses of variance were conducted for males and females, the ferritin concentration in the ZZ cohort was greater than both MM and MZ for males while only greater than MM subjects for females. Plasma transferrin for MM, MZ, and ZZ cohorts showed no significant differences between them regardless of whether all were included in the analysis or sex-specific values were considered (Figure 1C; F = 2.97; P = 0.09).

Linear regression analysis revealed a significant (negative) relationship between plasma concentrations of A1AT and ferritin (Figure 2A; r = 0.26; P = 0.01). Linear regression between A1AT and transferrin levels was not significant (Figure 2B; r = 0.18; P = 0.09). The linear regression between ferritin and transferrin was significant (negative) (Figure 2C; r = 0.39; P < 0.01).

Plasma CRP concentrations were not significantly different between MM, MZ, and ZZ individuals (Figure 3A). Linear regression analysis did not show a significant

Table 1 Demographics of healthy individuals providing plasma samples

<table>
<thead>
<tr>
<th></th>
<th>MM</th>
<th>MZ</th>
<th>ZZ</th>
</tr>
</thead>
<tbody>
<tr>
<td>Males (n)</td>
<td>7</td>
<td>10</td>
<td>14</td>
</tr>
<tr>
<td>Females (n)</td>
<td>23</td>
<td>20</td>
<td>16</td>
</tr>
<tr>
<td>Age (years ± standard deviation)</td>
<td>52.2 ± 14.1</td>
<td>48.9 ± 15.9</td>
<td>50.3 ± 17.4</td>
</tr>
<tr>
<td>Caucasian (n)</td>
<td>25</td>
<td>27</td>
<td>25</td>
</tr>
<tr>
<td>African American (n)</td>
<td>3</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

Notes: *Significant difference relative to the comparable sex-specific group of MM; **significant difference relative to the comparable sex-specific groups of MM and MZ.

Abbreviation: A1AT, α-1 antitrypsin.

Figure 1 Concentrations of A1AT, ferritin, and transferrin among MM, MZ, and ZZ cohorts. Relative to the MM genotype, significant decrements in plasma A1AT concentrations were observed in both MZ and ZZ subjects (A). Relative to MM subjects, plasma ferritin levels were significantly increased only in the ZZ cohort (B). Transferrin did not demonstrate differences between the three genotypes (C).

Notes: *Significant difference relative to the comparable sex-specific group of MM; **significant difference relative to the comparable sex-specific groups of MM and MZ.

Abbreviation: A1AT, α-1 antitrypsin.
association between CRP and A1AT (Figure 3B; $r = 0.10; P = 0.36$). Regarding the relationships between CRP and indices of iron homeostasis, there was no significant association with either ferritin ($r = 0.17; P = 0.11$) or transferrin ($r = 0.20; P = 0.06$).

Plasma metal concentrations were significantly different between MM and ZZ cohorts for aluminum ($F = 3.10; P = 0.05$) and iron ($F = 3.37; P = 0.04$) (Figure 4A). Zinc also appeared to increase in the ZZ cohort, but this did not reach significance ($F = 0.49; P = 0.61$). Aluminum and iron were elevated in those individuals with the ZZ genotype relative to the MM genotype; disparities between MM and MZ were not significant. In contrast, copper levels among those with both MZ and ZZ genotypes were significantly lower

---

**Figure 2** Linear correlations between plasma concentrations of A1AT, ferritin, and transferrin. The correlation between A1AT and ferritin concentrations (A) reached significance while that between A1AT and transferrin (B) did not. The relationship between plasma ferritin and transferrin was negative and significant (C).

**Figure 3** C-reactive protein (CRP) levels in MM, MZ, and ZZ individuals and its correlation with A1AT concentration. There were no significant differences in CRP among the MM, MZ, and ZZ genotypes (A). Similarly, there was no significant correlation between plasma A1AT and CRP concentrations (B).

**Abbreviation:** A1AT, α-1 antitrypsin.
relative to the MM cohort (F = 4.33; P = 0.02) (Figure 4A).
Correlations of plasma metal concentration with levels of
A1AT were significant only for iron (Figure 3B; r = 0.21;
P = 0.05).

Discussion
Ferritin is considered the best available index to measure
total body stores of iron.20–22 Significant differences in plasma
ferritin concentrations between MM and ZZ individuals sup-
port an impact of A1AT deficiency on iron homeostasis in
humans. Similarly, plasma iron levels were increased in the
ZZ genotype. While the MZ genotype decreased A1AT levels,
it did not influence ferritin and iron concentrations; this may
reflect either a true lack of effect of A1AT genotype on iron
homeostasis or the sample number may have been insuffi-
cient to demonstrate a difference. The significant correlations
between both plasma levels of ferritin and iron with A1AT
deficiency, iron homeostasis is disrupted.

This investigation does not address the molecular basis
for a disruption in iron homeostasis in patients with A1AT
deficiency. Proteases are employed as a third pathway of iron
acquisition by microbials (in addition to siderophores and
ferrireductases).23,24 These proteins have a capacity to cleave
iron-transport and -storage proteins thus allowing utilization
of the metal by the microbe.25–27 Reflecting potential inter-
actions between metal availability and proteases, increased
iron concentrations can impact expression and/or activity of
collagenase, elastase, alkaline proteinase, and metallopro-
teases.28–31 In addition, in vitro exposure to the protease
inhibitor A1AT alters iron homeostasis in eukaryotic cells.32–34
This serpin, which primarily inhibits neutrophil elastase, can
elevate intracellular ferritin concentrations in cultured cells.
In vivo exposure to protease disrupted iron homeostasis
in an animal model.17 Finally, among patients with A1AT
deficiency, iron homeostasis is disrupted.16,35,36 Accordingly,
one mechanism through which A1AT deficiency can affect a
disruption in iron homeostasis is by allowing an unrestricted
activity of specific proteases which would result in increased
iron availability. This will lead to elevated tissue concentra-
tions of iron especially in the liver and spleen, which are
major cites of storage. Reflecting this, blood ferritin will be
increased among individuals with A1AT deficiency.

This disruption in iron homeostasis associated with
A1AT deficiency can assist in understanding the clinical
presentation of such patients. Clinical manifestations of
A1AT deficiency most frequently include liver and lung
disease. Liver tissue is one of the major sites for iron storage.
With a lack of A1AT, there will be an accumulation of
iron with subsequent elevations in liver concentrations. Elevated liver iron is associated with hepatitis, cirrhosis, and hepatocarcinoma, which are the manifestations of disease in A1AT deficiency among ZZ individuals. Inhaled exposures (eg, particles) precipitate a biological effect in the lung by disrupting the normal iron homeostasis and increasing the availability of host iron.17 Subsequently, particle exposure in A1AT deficient individuals is predicted to be associated with a higher incidence of disease (eg, chronic obstructive pulmonary disease among smokers and those exposed to elevated particle levels).18-40

We conclude that A1AT deficiency is associated with evidence of a disruption in iron homeostasis in ZZ individuals with plasma ferritin and iron concentrations being elevated. Such a disruption in iron homeostasis can contribute to understanding the clinical presentation of A1AT deficiency.

Acknowledgments

We thank the Alpha-1 Foundation for allowing access to archived plasma samples.

Disclosure

Bernard Fischer was supported in part by an Alpha-1 Foundation research grant. The other authors have no conflict of interests to declare.

References


